
    
      This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix
      JV, LLC (BMX). It is a double-blind parallel cohort study designed to determine the safety
      and efficacy of BMX-010 (0.03%) relative to Placebo in subjects with atopic dermatitis and
      psoriasis.

      Subjects will be queried regarding adverse events (AEs) and concomitant medication usage.
    
  